Pharmaron

Allergan Biologics developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products.

Imago BioSciences is a clinical-stage biotechnology company based in San Carlos, California, focused on developing innovative therapies for hematologic diseases, including leukemia and myelodysplastic syndromes. Established in 2012, the company specializes in small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme crucial for blood cell production in the bone marrow. Its lead candidate, Bomedemstat, is an orally available inhibitor of LSD1, being evaluated for its potential to modify the disease course in patients with myeloproliferative neoplasms, a group of chronic bone marrow cancers. Imago aims to translate advanced scientific insights into effective treatments that can significantly improve the quality and duration of life for patients facing these challenging conditions.

Absorption Systems is a company that specializes in providing non-clinical contract research organization (CRO) services, focusing on the prediction of human outcomes related to drug absorption, distribution, metabolism, and excretion. With locations in Exton, Pennsylvania, San Diego, California, and Panama City, Panama, the company serves a diverse clientele, including small virtual pharmaceutical firms, large pharmaceutical companies, and specialty CROs seeking complementary services. Absorption Systems emphasizes a collaborative approach, working closely with clients to design studies and develop custom models tailored to their specific needs. This flexibility has fostered innovative solutions in drug discovery and development, enhancing the capabilities of pharmaceutical, biotech, and medical device companies, as well as regulatory agencies in their research and testing efforts.

Xceleron, founded in 1997 in York, UK, and now based in Germantown, Maryland, specializes in bioanalytical accelerator mass spectrometry (AMS) services to enhance drug development. The company pioneered techniques for human microdosing and microtracing, focusing on the pharmacokinetics and metabolism of developmental drugs during early clinical trial phases. Xceleron's services include micro-dosing, preclinical evaluation, intravenous pharmacokinetics, metabolite profiling, and mass balance investigations in humans. Their expertise is particularly valuable given the complexity of modern small molecules, which often exhibit low solubility and lengthy half-lives, necessitating early pharmacokinetic characterization to improve the cost-effectiveness of clinical development. Through a commitment to integrity and collaboration, Xceleron aims to accelerate the delivery of life-changing products to the market.

Quotient Bioresearch Limited is a contract research organization (CRO) based in Rushden, United Kingdom, specializing in early-stage and specialized drug development services for clients in the pharmaceutical, biotechnology, agrochemical, chemical, and animal health sectors. The company offers a comprehensive range of services, including integrated chemistry and metabolism programs, radiochemistry, drug metabolism, and environmental fate solutions. Its capabilities encompass tritium and stable isotope synthesis, carbon-14 synthesis, preclinical drug metabolism and pharmacokinetics (DMPK), metabolite analysis, and bioanalysis. Quotient Bioresearch provides tailored solutions to address the specific needs of its diverse clientele, leveraging advanced scientific, chemical, and biological expertise. Founded in 1992, the company operates as a subsidiary of Pharmaron, Inc., and has established a reputation for delivering high-quality services globally.

Bridge Laboratories, Inc. operates as a preclinical contract research organization. Its drug development and preclinical services include short and long-term in vivo studies ranging from acute to carcinogenicity protocols; and species and routes of administration.